KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovoCure (NVCR) Equity Ratio (2016 - 2026)

NovoCure's Equity Ratio history spans 13 years, with the latest figure at 0.42 for Q1 2026.

  • On a quarterly basis, Equity Ratio rose 44.81% to 0.42 in Q1 2026 year-over-year; TTM through Mar 2026 was 0.42, a 44.81% increase, with the full-year FY2025 number at 0.42, up 45.82% from a year prior.
  • Equity Ratio hit 0.42 in Q1 2026 for NovoCure, down from 0.42 in the prior quarter.
  • Over the last five years, Equity Ratio for NVCR hit a ceiling of 0.42 in Q4 2025 and a floor of 0.25 in Q3 2025.
  • Historically, Equity Ratio has averaged 0.34 across 5 years, with a median of 0.34 in 2023.
  • Biggest five-year swings in Equity Ratio: fell 16.79% in 2024 and later surged 45.82% in 2025.
  • Tracing NVCR's Equity Ratio over 5 years: stood at 0.37 in 2022, then fell by 14.57% to 0.32 in 2023, then decreased by 8.22% to 0.29 in 2024, then surged by 45.82% to 0.42 in 2025, then decreased by 0.84% to 0.42 in 2026.
  • Business Quant data shows Equity Ratio for NVCR at 0.42 in Q1 2026, 0.42 in Q4 2025, and 0.25 in Q3 2025.